Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.45 |
| ▸ | CTSB | P07858 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587775 | 0.90 | GAA (0.49) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL12128243 | 0.87 | GAA (0.46) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL11298235 | 0.86 | GAA (0.53) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL628459 | 0.86 | ALDH1A1 (0.46) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL12128276 | 0.86 | CTSL (0.47) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL1198001 | 0.86 | NOTUM (0.53) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL11954589 | 0.82 | GAA (0.50) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL16283601 | 0.82 | GAA (0.42) | GAACES2CTSLCTSBALDH1A1 | |
| SCHEMBL628084 | 0.81 | RXRA (0.43) | GAACTSLCTSBALDH1A1ASH1L | |
| SCHEMBL11300330 | 0.80 | GAA (0.44) | GAACES2MAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116514773-B | Verdinexor (KPT-335) and synthesis method of hydrochloride thereof | 重庆汉佩生物科技有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-116514773-A | Verdinexor (KPT-335) and synthesis method of hydrochloride thereof | 重庆汉佩生物科技有限公司 | 2023-08-01 | — | — | CN | claimed |
| US-11318120-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2022-05-03 | — | — | US | claimed |
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC. (US) | 2021-08-19 | — | — | US | claimed |
| US-12577225-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260062391-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12291508-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250059158-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2025-02-20 | — | — | US | disclosed |
| EP-3663291-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-116514773-B | Verdinexor (KPT-335) and synthesis method of hydrochloride thereof | 重庆汉佩生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376114-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2024-11-14 | — | — | US | disclosed |
| US-20240279188-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2024-08-22 | — | — | US | disclosed |
| EP-2419412-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-02-22 | — | — | EP | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2010120741-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | GAA 1566/4885CES2 3871/4885CTSL 4729/4885 |
| US-20240376114-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | GAA 2114/4885CES2 4047/4885CTSL 4822/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | GAA 3958/4885CES2 4629/4885CTSL 4706/4885 |
| US-12577225-B2 | Nuclear transport modulators and uses thereof | XPO1, XPOT, CSE1L | GAA 4336/4885CES2 4215/4885CTSL 4303/4885 |
| US-11318120-B2 | Nuclear transport modulators and uses thereof | XPO1, XPO5, XPOT | GAA 1566/4885CES2 3871/4885CTSL 4729/4885 |
| US-20260062391-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | SLC8A1, SLC9A1, SLC8B1 | GAA 3813/4885CES2 2337/4885CTSL 4575/4885 |
| US-20240279188-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, KPNA1, ABCB11 | GAA 1990/4885CES2 3364/4885CTSL 4846/4885 |
| US-20250059158-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | GAA 1013/4885CES2 3820/4885CTSL 4751/4885 |
| US-12291508-B2 | Hydrazide containing nuclear transport modulators and uses thereof | XPO1, KPNA1, ABCB11 | GAA 1990/4885CES2 3364/4885CTSL 4846/4885 |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | GAA 4433/4885CES2 3076/4885CTSL 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.